• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

REPAGLINIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • REPAGLINIDE chembl:CHEMBL1272 Approved

    Alternate Names:

    NOVONORM
    AG-EE 623 ZW
    ENYGLID
    AG-EE-623-ZW
    AG-EE-623ZW
    A10BX02
    REPAGLINIDE
    AGEE-623ZW
    PRANDIN
    REPAGLINIDA
    (-)-REPAGLINIDE
    REPAGLINIDUM
    PRANDIN®
    SUREPOST
    AG-EE 388 ZW
    pubchem.compound:65981
    rxcui:73044
    chembl:CHEMBL1272
    drugbank:00912
    chemidplus:135062-02-1

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidiabetic
    Drug Class hypoglycemic agents
    Year of Approval 1997
    (3 More Sources)

    Publications:

    Rodríguez-Antona C et al., 2008, Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism., Pharmacogenomics J
    Niemi M et al., 2003, Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide., Clin Pharmacol Ther
    Tomalik-Scharte D et al., 2011, Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide., Drug Metab Dispos
    Tornio A et al., 2008, The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo., Clin Pharmacol Ther
    Niemi M et al., 2005, Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics., Clin Pharmacol Ther
    Yu M et al., 2010, KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes., Clin Pharmacol Ther
    Hu et al., 2000, Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide., J. Pharmacol. Exp. Ther.
    Wängler et al., 2004, Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET)., Nucl. Med. Biol.
    Hansen et al., 2002, Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1., Diabetes
    Wängler et al., 2004, Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent., Bioorg. Med. Chem. Lett.
    Sunaga et al., 2001, The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide., Eur. J. Pharmacol.
    Dornhorst, 2001, Insulinotropic meglitinide analogues., Lancet
    Du QQ et al., 2013, PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers., Eur J Clin Pharmacol
    Huang Q et al., 2010, Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients., Eur J Clin Pharmacol
    Dai XP et al., 2012, KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients., Clin Exp Pharmacol Physiol
  • REPAGLINIDE   SLC30A8

    Interaction Score: 8.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20809084


    Sources:
    PharmGKB

  • REPAGLINIDE   IGF2BP2

    Interaction Score: 4.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • REPAGLINIDE   ABCC8

    Interaction Score: 2.18

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name repaglinide,Prandin, NovoNorm, PrandiMet
    Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker

    PMIDs:
    10773014 15219283 12196472 15380228 11716850 11728565


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • REPAGLINIDE   PAX4

    Interaction Score: 2.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • REPAGLINIDE   TCF7L2

    Interaction Score: 1.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20054294


    Sources:
    PharmGKB

  • REPAGLINIDE   NEUROD1

    Interaction Score: 1.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • REPAGLINIDE   CYP2C8

    Interaction Score: 0.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17923851 14534525 21270106 18388877 15961978


    Sources:
    PharmGKB

  • REPAGLINIDE   NOS1AP

    Interaction Score: 0.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • REPAGLINIDE   KCNQ1

    Interaction Score: 0.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22414228


    Sources:
    PharmGKB

  • REPAGLINIDE   KCNJ11

    Interaction Score: 0.59

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker
    Direct Interaction yes

    PMIDs:
    20054294


    Sources:
    ChemblInteractions TEND PharmGKB

  • REPAGLINIDE   ABCC9

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • REPAGLINIDE   KCNJ1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • REPAGLINIDE   NR1I2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23807564


    Sources:
    PharmGKB

  • REPAGLINIDE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • REPAGLINIDE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: REPAGLINIDE

    • Version: 01-August-2011

    Alternate Names:
    REPAGLINIDE Primary Drug Name

    Drug Info:
    Year of Approval 1997
    Drug Class hypoglycemic agents

    Publications:

  • TdgClinicalTrial: REPAGLINIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidiabetic
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: repaglinide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Huang Q et al., 2010, Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients., Eur J Clin Pharmacol
    Yu M et al., 2010, KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes., Clin Pharmacol Ther
    Dai XP et al., 2012, KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients., Clin Exp Pharmacol Physiol

  • DTC: REPAGLINIDE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1272 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Repaglinide

    • Version: 2020.06.01

    Alternate Names:
    D0N5YA TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1272

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1272

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21